Mytien Nguyen[/caption]
Mytien Nguyen, MS
Department of Immunobiology,
Yale School of Medicine
New Haven, Connecticut
MedicalResearch.com: What is the background for this study?
Response: Physician-scientists are critical for innovative translational research. Combined MD-PhD training programs are essential for developing physician-scientists. Although racial and ethnic diversity of MD-PhD matriculants has increased over the past decade, little is known about how attrition rates differ by race and ethnicity.
Dr. Reed[/caption]
Nicholas S. Reed, AuD PhD
Assistant Professor | Department of Epidemiology
Johns Hopkins University Bloomberg School of Public Health
MedicalResearch.com: What is the background for this study?
Response: To date, national estimates of hearing loss have often been based on self-report, which is a fine metric in its own right but underestimates the prevalence of hearing loss against criterion standard measures, and most studies with criterion-level hearing measures are limited to relatively younger samples of older adults. For example, some previous nationally representative samples don't allow reporting age data over 80 years because there aren't enough participants in that age group. It is not surprising given that it is difficult to design nationally representative studies that truly allow older adults (80+ years) to participate and measuring hearing can be onerous. However, understanding the prevalence of hearing loss in this age group is vital for public health and policy planning efforts to address hearing loss at the national level.
Response: In 2021, USDA launched a plan to investigate exposure of wild white-tailed deer (Odocoileus virginianus) to SARS-CoV-2, a zoonotic virus and the virus that causes COVID-19. Researchers found that 40% of the blood samples tested had SARS-CoV-2 antibodies. This initial study suggested that SARS-CoV-2 could be transmitted from humans to deer, and that deer could potentially serve as a reservoir for the virus.
To better understand the transmission of SARS-CoV-2 in white-tailed deer, a team of researchers conducted a larger study to collect and analyze respiratory samples from free-ranging white-tailed deer in the United States. The study identified SARS-CoV-2 sequences in white-tailed deer across nearly half of the states in the U.S. The researchers also found that deer could be infected with multiple SARS-CoV-2 lineages, and that these lineages could be transmitted from deer to deer.
In addition, the researchers found three cases of potential virus transmission from white-tailed deer back to humans. This raises concerns about the potential for the virus to continue to evolve in an animal reservoir, and the possibility of future spillover events.
Poznan University of Medical Sciences carried out a study involving 171 participants over a period of 18 months. The participants were split into two groups. One group used hydroxyapatite (fluoride-free) toothpaste and the other group used fluoridated toothpaste throughout the study. Six-monthly trips to a dental clinician were completed and a DIAGNOcam device and plaque-disclosing solution were used to check for signs of cavities and plaque. The end results revealed that almost 90% of people in both groups had no new cavities, which indicates that both hydroxyapatite toothpaste and fluoridated toothpaste keep cavities at bay.
Dr. Li Li[/caption]
Li Li, M.D., Ph.D., M.P.H
Walter M. Seward Professor
Chair of Family Medicine
Director of population health
University of Virginia School of Medicine
Editor-in-chief of The BMJ Family Medicine
Dr. Li joined the U.S. Preventive Services Task Force in January 2021
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The Task Force reviewed the latest available evidence to evaluate whether screening all children and adolescents who are 20 years old or younger for high cholesterol improves their heart health into adulthood.
At this time, there is not enough evidence to determine whether or not screening all kids is beneficial, so we are calling for additional research on the effectiveness of screening and treatment of high cholesterol in kids and teens.
Dr. Davis[/caption]
Prof. Jonathan Davis, MD,
Chief of Newborn Medicine
Tufts Medical Center and
[caption id="attachment_60599" align="alignleft" width="125"]
Dr. Maron[/caption]
Jill Maron, MD, MPH
Chief of Pediatrics
Women & Infants Hospital of Rhode Island
MedicalResearch.com: What is the background for this study?
Response: The Genomic Medicine for Ill Neonates and Infants (GEMINI) trial was designed to be the first comparative study to explore the diagnostic yield, clinical utility and time to diagnosis between whole genomic sequencing (WGS) and a targeted genomic sequencing panel specifically designed to detect gene disorders that present in early life. GEMINI was a US based study that enrolled 400 hospitalized infants, along with their available parents, suspected of having an undiagnosed genetic diagnosis. Every participant underwent testing on each platform simultaneously, allowing us to better understand the limitations and advantages of each approach.
Dr. Lessa[/caption]
Fernanda Lessa, MD, MPH
Chief, CDC’s International Infection Control Program
Co-author of the paper
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Data from low- and middle-income countries on the impact of the COVID-19 pandemic on antibiotic use among outpatients are sparse.
This study evaluated the changes in prescribing rates of antibiotics commonly prescribed for respiratory tract infections by outpatient providers among adults in Brazil. We observed increases during the pandemic in outpatient prescriptions of azithromycin and ceftriaxone of up 360% and 90%, respectively, based on age and sex.
Dr. Potnuru[/caption]
Paul Potnuru, MD
Assistant Professor
Anesthesiology, Critical Care and Pain Medicine
The John P. and Kathrine G. McGovern Medical School
The University of Texas Health Science Center at Houston
UTHealth
MedicalResearch.com: What is the background for this study?
Response: The use of cannabis is on the rise in the United States, as it becomes increasingly legally accepted and is viewed as harmless. Furthermore, the potency of cannabis is steadily increasing over time.
There is some evidence from previous studies that compared to non-users, cannabis users require more anesthetics, have higher pain after surgery that requires more opioids, and have an increased risk of postoperative nausea and vomiting.
Given this context of increased usage and potential risks during surgery, we conducted a study to examine the impact of cannabis use on patients undergoing surgery.
Dr. Fink[/caption]
Dorothy A. Fink, MD
Deputy Assistant Secretary for Women's Health
Director, Office on Women's Health
US Department of Health & Human Services
Rockville, MD
MedicalResearch.com: What is the background for this study?
Response: Delivery-related mortality in U.S. hospitals has decreased for all racial and ethnic groups, age groups, and modes of delivery while the prevalence of severe maternal mortality (SMM) increased for all patients, with higher rates for racial and ethnic minority patients of any age.
This study specifically looked at inpatient delivery-related outcomes and found a 57% decrease from 2008-2021. The decreasing mortality rates within the inpatient delivery setting demonstrated as statistically significant and a welcome finding for all women.
This study also looked with greater granularity at the impact of race, ethnicity, and age. Mortality for American Indian women decreased 92%, Asian women decreased 73%, Black women decreased 76%, Hispanic women decreased 60%, Pacific Islander women decreased 79%, and White women decreased 40% during the study period.
Edward Liu[/caption]
Edward Liu, BA
Second year medical student
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: The use pattern of two FDA approved cannabinoids, dronabinol (Marinol) and cannabidiol (Epidiolex) has not been previously studied. Dronabinol has been approved in the United States since 1985 for chemotherapy induced nausea as well as vomiting and HIV-induced anorexia,1,2 whereas cannabidiol has been approved since 2018 to treat childhood epileptic disorders, Lennox-Gastaut and Dravet syndrome.3 This longitudinal study examined Medicaid claims between 2016-2020 for these two prescription cannabinoids to better comprehend the state-level pharmacoepidemiologic trends and distribution of these drugs in US Medicaid amidst the increasing use of non-pharmaceutical formulations of cannabis.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. Hearing loss can tremendously impact an individual’s quality of life, making...
Valentina Paz[/caption]
Valentina Paz, M.Sc Ph.D. Student
Research and teaching assistant
Universidad de la República, UruguayHon. Research Assistant
Dr. Ogedegbe[/caption]
Gbenga Ogedegbe, MD, MPH
Dr. Adolph & Margaret Berger Professor of Population Health
Director, Division of Health & Behavior
Director Center for Healthful Behavior Change
Department of Population Health
NYU Langone Health
NYU School of Medicine
Member of the U.S. Preventive Services Task Force
MedicalResearch.com: What is the background for this study?
Response: Depression and anxiety disorders are common mental health conditions affecting the lives of many adults in the U.S. The Task Force cares deeply about the health of people nationwide, so we reviewed the latest evidence on how best to support the mental health of adults in primary care.
MedicalResearch.com: What are the main findings?
Response: The evidence shows us that all adults should be screened for depression and those under 65 should also be screened for anxiety. These recommendations apply to everyone without signs or symptoms of depression or anxiety. We also strongly encourage anyone who has signs of depression or anxiety to talk with their clinician so that they can get the care they need.
Dr. Zahedi[/caption]
Dr. Bita Zahedi MD MA
Endocrinologist
Massachusetts General Hospital
MedicalResearch.com: What is the background for this study?
Response: The purpose of this study was to develop and validate a measure of dietary advanced glycation end-products (AGEs) to investigate the role of dietary AGEs in diabetic disease processes. AGEs are a group of highly reactive compounds involved in the pathophysiology of diabetic complications, such as microvascular disease, cardiomyopathy, and possibly bone health. AGEs form through a nonenzymatic reaction between reducing sugars and free amino groups of proteins, lipids, and nucleic acids, also known as a Maillard or browning reaction.
Endogenous AGE formation and accumulation is a normal part of metabolism and aging, however the process of glycation can be enhanced by hyperglycemia, hyperlipidemia, and increased oxidative stress. Additionally, AGEs can be absorbed from exogenous sources via consumption of various food items. Prior studies demonstrate that skin AGEs are predictive of Dietary AGEs (dAGEs) which are naturally present in certain uncooked foods, mainly animal-derived products, furthermore the method of food preparation can result in significant AGE formation. Considering the ubiquitous intake of dAGEs, it is possible that the consumption of exogenous AGEs contribute to AGE-induced oxidative stress, inflammation, and its subsequent detrimental sequalae.
Dr. Ly[/caption]
Dan P. Ly, MD, PhD, MPP
Physician and an Assistant Professor
Division of General Internal Medicine and Health Services Research
David Geffen School of Medicine at UCLA
MedicalResearch.com: What is the background for this study?
Response: Cognitive biases, or ways of thinking that may deviate from rationality, are thought to influence physician decision-making, but there has been little large-scale evidence of their existence clinically. There is some large-scale evidence of the availability heuristic, under which the likelihood of an event is affected by how easily it comes to mind, but there’s little large scale evidence of other cognitive biases affecting physicians.
Dr. Miller[/caption]
Alex P. Miller, PhD
TranSTAR T32 Postdoctoral Fellow
Department of Psychiatry
Washington University School of Medicine
St. Louis, MO
MedicalResearch.com: What is the background for this study?
Response: Adolescent cannabis use is increasing in the United States. Prior research suggests that people who start using cannabis earlier are more likely to engage in problematic use and also experience greater mental health challenges and socioeconomic disadvantages overall. For example, children who begin using cannabis early are more likely to have behavioral problems and disorders and are more less likely to complete school.
In our study, we used data from the Adolescent Brain Cognitive Development (ABCD) Study, which is following nearly 12,000 kids across the nation to track behavior and brain development as well as health from middle childhood to young adulthood. We looked at what factors are associated with the initiation of cannabis use by age 12-14.
Individuality is the buzzword on the current aesthetic medicine scene at a time in which the arrival of the remote working phenomenon has sparked an interest in more facial surgery and procedures delivering a more natural effect. The American Society of Plastic Surgeons (ASPS) has reported that there has been a boom in facial feature surgery such as facelifts, blepharoplasties, and rhinoplasties. What’s more, although breast augmentations, liposuctions, and buttock augmentations continue to be in high demand, the results sought are no longer driven by celebrity trends. Instead, they are firmly focused on results that are in harmony with a patient’s physique. Finally, many clients are completely giving the knife a miss and opting for non- or minimally-invasive treatments that deliver great results. Below are the top trends taking over the sector. You may consider advice from a female plastic surgeon in Houston.
Dr. Hafezi-Moghadam[/caption]
Ali Hafezi-Moghadam, Ph.D., M.D
Director, Molecular Biomarkers Nano-Imaging Laboratory (MBNI)
Associate Professor of Radiology, Harvard Medical School
Brigham and Women’s Hospital
MedicalResearch.com: What is the background for this study?
Response: “It is very easy to answer many fundamental biological questions” said Richard Feynman in his 1959 address, where he also offered his simple and ingenious solution: “you just look at the thing!”[1].
As a biologist, I am familiar with the challenges surrounding looking at things in the context of life. There is no single device or technology that lets me simply see the answers to my questions. How does diabetes harm the tissues in the body? When exactly does the pathology start and which molecules and cells are involved? Trying to answer these questions, I have spent the past two decades innovating new ways of quantifying expression of molecules in the living organism [2].
At the same time to study diabetes, we needed a realistic rodent model that mirrors the human disease. In collaboration with KC Hayes[3], we first introduced the Nile grass rat (NGR, Arvicanthis niloticus), a gerbil that recapitulates the main features of the human type 2 diabetes [4]. For visualization of early changes, the eye offers a unique site. Much of my lab’s work focused on the first effects of diabetes in the retina, the site of the neurons that perceive light in the back of the eye [5], [6], [7]. In recent studies, we focused on how diabetes affects the lens in the eye of our animals [8], [9].
Diabetes is a major risk factor for cataract formation, a condition during which the lens loses its original transparency to visible light. How diabetic cataracts are formed is not well understood. A popular and prevailing theory, termed “sugar cataracts”, has been around for over half a century. According to the sugar hypothesis of cataracts, the excess levels of the sugar molecule, glucose, in the lens are transformed through the polyol pathway into the sugar-alcohol sorbitol. The resulting osmotic dysbalance leads to swelling of the fiber cells and opacity of the lens. Even though the sugar hypothesis has never been proven, it was generally accepted and remained unchallenged for a very long time. That is where our latest experimental results became relevant.
Dr. GALBIATI[/caption]
Francesca Galbiati, MD
Clinical/Research fellow in Endocrinology
Massachusetts General Hospital
MedicalResearch.com: What is the background for this study?
Response: Arginine-vasopressin (AVP) is a neurohormone well known for its role in water balance regulation. It promotes renal water absorption in the kidney, to maintain normal sodium levels in the blood via a tightly controlled osmotic regulation. Besides AVP classical role, data have shown that AVP effects extend beyond water balance regulation. Animal studies have shown that AVP has metabolic effects, including reducing food intake, inducing lipolysis, and promoting muscle regeneration in male mice.
Furthermore, AVP is regulated differently in males and females, and affects cognition differently across sexes, a phenomenon called sexual dimorphism. However, it is unknown whether its dimorphism translates to metabolism. Also, findings on AVP metabolic role are inconsistent, possibly due to the opposing effects of AVP at different receptor subtypes, which regulation is still largely unknown. We performed this study to better investigate AVP metabolic role, and explore sex differences. We hypothesized that AVP would be positively associated with BMI, adiposity, and lean mass (acting as a signal of energy availability). We also predicted that relationships between AVP and body composition measures would differ by sex. We used the AVP area under the curve around a standardized meal to better capture repeated measures in response to food intake (that directly impacts energy availability). This also allowed to avoid the possible risk of fluctuating AVP levels due to possible pulsatile secretion.
Dr. Thomas[/caption]
Dr. Daniel Thomas MD PhD FRACP FRCPA
Program Leader, Blood Cancer
Precision Medicine Theme at the South Australia Health Medical Research Institute
Clinical Hematologist, Royal Adelaide Hospital
Associate Professor, Adelaide Medical School, The University of Adelaide
MedicalResearch.com: What is the background for this study? Would you briefly describe the condition of CMML?
Response: Chronic myelomonocytic leukemia (CMML) is a rare, but increasingly frequent, clonal stem cell disorder that results in hyperproliferation of inflammatory monocytes, a form of white blood cells. It features both myelodysplasia and myeloproliferation. CMML is most often found in older adults and leads to anemia, decreased quality of life, and an increased risk of acute myeloid leukemia (AML).
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that stimulates production, growth, differentiation, activation, and function of myeloid cells (monocytes, neutrophils, and eosinophils). In the presence of RAS-pathway mutations, a greater sensitivity to GM-CSF contributes to the hyperproliferation of myelocytes in myelodysplastic leukemias such as CMML, juvenile myelomonocytic leukemia (JMML), and acute myeloid leukemia (AML). In CMML, greater sensitivity to GM-CSF stimulates excessive monocytic precursor proliferation.
The PREACH-M Trial, which stands for PREcision Approach to CHronic Myelomonocytic Leukemia, assesses the efficacy of lenzilumab in addition to azacitidine in treatment-naïve CMML participants with RAS-pathway mutations (KRAS, NRAS, CBL) and separately high dose ascorbate in participants with TET2 mutations who do not have RAS-pathway mutations. The study is currently underway and actively enrolling. It is being conducted and funded by the South Australian Health and Medical Research Institute (SAHMRI).
Dr. Whiteley[/caption]
Alexandra M Whiteley PhD
Department of Biochemistry
University of Colorado Boulder
Boulder, Colorado
MedicalResearch.com: What is the background for this study?
Response: My laboratory was interested in understanding how UBQLN2 maintains cellular health. Ubiquilins facilitate protein degradation, but the precise proteins that they help to break down were not well understood. UBQLN2 is of particular interest because mutations in the UBQLN2 gene lead to a familial form of ALS.
This project, which was published in eLife this year, stems from work that was published when I was a postdoctoral researcher at Harvard Medical School, where we found a link between UBQLN2 and the virus-like protein PEG10. Now at the University of Colorado, Boulder, my laboratory has focused on trying to understand this connection between the two proteins, and how PEG10 could contribute to ALS.
Dr. Kamath[/caption]
Dr. Suneel Kamath MD
Gastrointestinal Oncologist
Cleveland Clinic
Senior Author on this research
MedicalResearch.com: What is the background for this study?
Response: Colorectal cancer rates in young people under age 50 are skyrocketing and have been for the last 3-4 decades. We really don’t understand why because most cases (probably around 70%) are not genetic or hereditary, just random, unfortunate events. We suspect that it is some exposure(s) like excess consumption of red meat, processed foods, sugar-sweetened beverages, excess antibiotic use altering the microbiome, rising incidence of obesity or some other factors. We really don’t know why yet.
Our study used a technology called metabolomics, the study of breakdown products and production building blocks for our bodies, to look for differences in colorectal cancer in young people versus people that are older that developed colorectal cancer. Because metabolomics measures how each individual interacts with the exposures in our environment like diet, air quality, etc., it is a way to bridge the gap between our nature (determined by genetics) and nurture (determined by our exposures).
Dr. Graff[/caption]
Rebecca E. Graff, ScD
Assistant Professor
University of California, San Francisco
Department of Epidemiology & Biostatistics
Mission Hall: Global Health & Clinical Sciences Building
San Francisco, CA 94158
MedicalResearch.com: What is the background for this study?
Response: PSA screening for prostate cancer has long been controversial. While it does seem to reduce mortality attributable to prostate cancer, it also results in the diagnosis of many cancers that never otherwise would have presented symptomatically. In addition, PSA levels are affected by factors other than prostate tumors (e.g., age, prostatic inflammation, and genetics), such that men with high PSA values are often referred for biopsy but do not end up having cancer. We hypothesized that accounting for the genetic component of PSA could yield adjusted values that better distinguish who should get a prostate biopsy.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle, When you are giving blood you might be told that you...
Dr. Nowell[/caption]
W. Benjamin Nowell PhD
Director of Patient-Centered Research at Global Healthy Living Foundation
Columbia University in the City of New York
New York, New York
MedicalResearch.com: What is the background for this study?
Response: Given that lab tests are an important part of rheumatoid arthritis (RA) diagnosis and monitoring, people living with the condition want and need to understand their lab results –also known as blood work – for patient-centered shared decision making about treatment. The presentation titled, “Patient Perceptions of Rheumatoid Arthritis Blood Work and Utility of a Test Predicting Response to New Medication: A Cross-sectional Survey in the ArthritisPower,” presented at the 76th EULAR European Congress of Rheumatology (June 2, 2023 in Milan, Italy) includes results from a recent ArthritisPower survey (n=405) that asked patients to share their perceptions about RA bloodwork, reasons their doctor orders these tests, and how results are used.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. MedicalResearch.com does not endorse any particular health care provider. Breast augmentation...
Dr. Kurian[/caption]
Allison W. Kurian, M.D., M.Sc.
Professor of Medicine and of Epidemiology and Population Health
Associate Chief, Division of Oncology
Co-Leader, Population Sciences Program, Stanford Cancer Institute
Director, Women’s Clinical Cancer Genetics Program
Stanford University School of Medicine
Stanford, CA 94305-5405
MedicalResearch.com: What is the background for this study? What types of cancers were in the study?
Response: Genetic testing for cancer risk is increasingly important after a cancer diagnosis, to inform use of targeted therapies, secondary cancer prevention approaches and cascade genetic testing of family members. However, very little is known about how genetic testing is used after a cancer diagnosis at the population level. We leveraged a very large population-based data resource, the Surveillance, Epidemiology and End Results (SEER) cancer registries of the states of California and Georgia, and linked data from these registries to clinical genetic testing results provided by the four major laboratories that provide such testing. We used this linked registry-genetic testing dataset to study adults (age >=20 years) diagnosed with all types of cancer in the states of Georgia and California from 2013-2019.
Dr. Lova Sun[/caption]
Lova L. Sun, MD, MSCE
Medical Oncology
Assistant Professor of Medicine
Hospital of the University of Pennsylvania
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: An common clinical question for patients with metastatic non-small cell lung cancer with long-term response to immunotherapy-based treatment is how long to continue treatment. The major clinical trials stopped immunotherapy at a maximum of 2 years, but in clinical practice many patients and clinicians continue treatment beyond this time point.
We conducted a retrospective study of lung cancer patients across the US with long-term response to immunotherapy, to compare survival between those who stopped treatment at 2 years vs those who continued beyond 2 years. We found that there was no statistically significant difference in survival between the two groups.